Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Shanghai Seme Cell Technology Co. Ltd. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is characterized by a high degree of distribution, as the active cases are spread across 3 distinct examiners and 3 distinct art units. This suggests that the company's patent applications cover a diverse range of biotechnological innovations, requiring specialized review from multiple different technical groups within the patent office. The lack of overlap between examiners and art units indicates that each application is being treated as a distinct technical entity.
The busiest examiner for this portfolio is STEELE, AMBER D, who is responsible for 1 pending office action. Since there are 3 distinct examiners for the 3 pending office actions, the workload is distributed such that no single examiner has a disproportionate influence on the company's overall prosecution outcomes. For a practitioner, this means that strategies must be customized for each assigned individual and their respective art units. Navigating multiple art units requires an understanding of various internal policies and examination trends, as the pending filings are not centralized under a single authority.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| BOECKELMAN, JACOB A | 1 | 34.9% | +46.5% |
| UNDERDAHL, THANE E | 1 | 58.8% | +50.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18252254 | THERAPEUTIC APPLICATION OF CELL-FREE FAT EXTRACT TO ARTHRITIS | UNDERDAHL, THANE E | 14d |
| 18556310 | MEDICATION FOR TREATING LUNG INJURY | STEELE, AMBER D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039639 | THERAPEUTIC USE OF CELL-FREE FAT EXTRACT FOR OSTEOPOROSIS | BOECKELMAN, JACOB A | 24d overdue |
| 18252254 | THERAPEUTIC APPLICATION OF CELL-FREE FAT EXTRACT TO ARTHRITIS | UNDERDAHL, THANE E | 14d |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1655 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556310 | MEDICATION FOR TREATING LUNG INJURY | STEELE, AMBER D | 1658 | §102§103Other | Final Rejection | — | Pending | Oct 19, 2023 |
| 18039639 | THERAPEUTIC USE OF CELL-FREE FAT EXTRACT FOR OSTEOPOROSIS | BOECKELMAN, JACOB A | 1655 | §103 | Non-Final OA | 24d overdue | Pending | May 31, 2023 |
| 18252254 | THERAPEUTIC APPLICATION OF CELL-FREE FAT EXTRACT TO ARTHRITIS | UNDERDAHL, THANE E | 1699 | §102§103§112 | Final Rejection | 14d | Pending | May 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Seme Cell Technology Co. Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Amber D Steele has the most, with 1 of Shanghai Seme Cell Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
